Tesofensine
NS2330 / TE
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) first developed for Alzheimer's and Parkinson's disease and then studied for obesity. In a 24-week phase 2 trial, 0.5–1 mg daily produced 9.2–10.6 percentage points more weight loss than placebo (placebo-adjusted; placebo loss was 2%), with a rise in heart rate. It is not approved in the US or Europe.
Half-life
~220 hours (~9 days)
Typical Dose
0.25–0.5 mg/day oral
0.3/0.5Route
oral
Category
metabolic
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How Tesofensine is dosed in practice
Usually taken by mouth. Typical range: 0.25–0.5 mg/day oral. Half-life: ~220 hours (~9 days). Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
In a 24-week phase 2 obesity trial (2008), 0.5 mg and 1.0 mg daily produced 9.2–10.6 percentage points more weight loss than placebo (placebo-adjusted; placebo loss was 2%), with a heart-rate rise of about 7 beats per minute at 0.5 mg; the journal later added an expression of concern (2013). Not approved in the US or Europe.
- Phase 2 randomized trial in obesity (2008)
- Energy-expenditure study (2010)
Obesity medicine specialists view tesofensine as highly effective but with cardiovascular risk that requires careful patient selection. The extremely long half-life (~9 days) means steady state takes ~6 weeks and effects persist long after discontinuation. Start at 0.25 mg and assess cardiovascular response before increasing.
- Obesity medicine specialist clinical experience
- Cardiovascular safety review of monoamine reuptake inhibitors
- Weight loss clinic protocols for investigational compounds
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for Tesofensine and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Uncontrolled hypertension or cardiovascular disease (increases heart rate)
- History of major depressive disorder with suicidal ideation
- Concurrent use of MAO inhibitors or other monoamine reuptake inhibitors
- Glaucoma
Tesofensine: common questions
What is Tesofensine?
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) first developed for Alzheimer's and Parkinson's disease and then studied for obesity. In a 24-week phase 2 trial, 0.5–1 mg daily produced 9.2–10.6 percentage points more weight loss than placebo (placebo-adjusted; placebo loss was 2%), with a rise in heart rate. It is not approved in the US or Europe.
How is Tesofensine dosed?
Tesofensine is usually taken by mouth. Typical range in DoseCraft's library: 0.25–0.5 mg/day oral. Clinical (human trials): 0.25–1 mg/day oral; Once daily; 24 weeks (phase 2 trial). Expert (practitioner protocols): 0.25 mg/day, increase to 0.5 mg if tolerated; Once daily; 24+ weeks for full efficacy. These ranges describe what has been studied or used; they are not a prescription.
Is Tesofensine FDA-approved?
No. Tesofensine is not FDA-approved; it is in phase 3 clinical trials.
What is the half-life of Tesofensine?
DoseCraft's library lists a half-life of ~220 hours (~9 days). Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use Tesofensine?
Listed contraindications: Uncontrolled hypertension or cardiovascular disease (increases heart rate); History of major depressive disorder with suicidal ideation; Concurrent use of MAO inhibitors or other monoamine reuptake inhibitors; Glaucoma.
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.